Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

850.81 +37.28 (+4.58%)
Streaming Delayed Price Updated: 2:41 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
Eli Lilly's Options Frenzy: What You Need to Know
 
Via Benzinga
Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel
Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease progression and cognitive decline. 
Via Benzinga
A New Obesity Contender From China Targeting Same Receptors As Eli Lilly's Blockbuster
 
Via Benzinga
The 3 Things That Matter for Eli Lilly Now
Via The Motley Fool
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
The entire healthcare sector has fallen into a deeply discounted valuation, creating opportunities for investors who hunt for value and upside 
Via MarketBeat
Topics Artificial Intelligence
Americans Are Turning To DIY Weight Loss Injections to Dodge $1,000+ Monthly Drug Costs
 
Via Benzinga
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results
The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst. 
Via Investor's Business Daily
2 Vanguard ETFs That Can Turn $400 per Month Into Over $1.7 Million
Exchange-traded funds (ETFs) can be a lucrative source of wealth for patient investors. 
Via The Motley Fool
Topics ETFs
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs. 
Via Benzinga
Topics Government
Better Growth Buy: Eli Lilly vs. Viking Therapeutics
Via The Motley Fool
2 Beaten-Down Dividend Growth Stocks to Buy on the Dip
Via The Motley Fool
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results
Via The Motley Fool
5 Monster Stocks to Hold for the Next 25 Years
Buy-and-hold investing only works if you choose the right companies. Here are some potential examples. 
Via The Motley Fool
Topics Artificial Intelligence Economy
AstraZeneca Bets Big On America With $50B Investment, New Virginia Hub Plans Amid Pharma Tariff Jitters
At the center of the company’s plan is a new, multi-billion-dollar manufacturing facility in Virginia. 
Via Stocktwits
Topics Artificial Intelligence Government World Trade
Should You Invest in This Under-the-Radar Weight Loss Stock?
Via The Motley Fool
Here's Why Vanguard's Worst-Performing Sector ETF Is a No-Brainer Buy Right Now
Via The Motley Fool
Topics Artificial Intelligence ETFs
Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.
Via The Motley Fool
Topics Government World Trade
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note. 
Via The Motley Fool
Topics Intellectual Property
Can Eli Lilly Stock Withstand the Threat of President Trump's New Sweeping Tariffs?
Via The Motley Fool
Topics Earnings Government World Trade
Top S&P500 movers in Thursday's session
Curious about the top performers within the S&P500 index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off
Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and nationwide delivery. 
Via Benzinga
Ozempic, Mounjaro Users Cut $6.5 Billion From Grocery Bills: GLP-1 Boom Triggers Panic In Packaged Food Aisles
GLP-1 medications are delivering a $6.5 billion blow to U.S. grocery spending, with weight-loss drugs altering consumer purchasing patterns. 
Via Benzinga
1 Volatile Stock with Exciting Potential and 2 to Question
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced... 
Via StockStory
What's going on in today's session: S&P500 movers
Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
WeightWatchers (WW) Stock Trades Up, Here Is Why
Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 4.1% in the morning session after the company successfully completed its strategic reorganization process and announced new program... 
Via StockStory
Topics Bankruptcy Initial Public Offering
$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk. 
Via Benzinga
Topics Government World Trade
PolyPid’s Game-Changing 60-Day GLP-1 Platform Could Disrupt $100B Weight Loss Market
Via AB Newswire
Palatin’s Oral Obesity Drug Shows Remarkable Results: The Hidden Gem in the Weight Loss Race
Via AB Newswire
Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook
Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO. 
Via MarketBeat
Topics Economy Stocks
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.